Abstract
Abstract: Colon cancer claims the third rank in the list of most common cancers diagnosed in the United States. Literature findings suggest that certain proteins are highly expressed in a specific type of cancer. Therefore, there is a need to discover drugs that are specific against specific proteins in colon cancer. However, most of the anti-cancer drugs in the market are known to exhibit severe side effects. Hence new molecules with maximal efficiency of binding towards proteins expressed in colon cancer would be an advantage. In this study, a novel approach has been implemented to screen the existing drugs in the market versus highly expressed proteins in colon cancer and apoptosis. This study revealed five drugs, such as Olmesartan, Verteporfin, Ritonavir, Telmisartan, and Eprosartan respectively as probable anti-cancer agents based on the molecular dock scores obtained when compared with bounds ligands of each protein.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal for Research in Applied Science and Engineering Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
